Jaguar Gene Therapy
Jaguar Gene Therapy is dedicated to accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. They leverage expertise and best-in-class manufacturing processes to develop safe, effective therapies, aiming to bring innovative treatments from bench to bedside rapidly and safely. Their mission is driven by core values of integrity, agility, and collaboration, with a focus on product purity and patient safety. The company has assembled a team of experts with extensive experience in gene therapy, including those who have led the development and approval of systemic gene therapies. They target devastating genetic diseases with significant unmet needs and continuously evaluate next-generation technologies and partnerships to expand their pipeline and capabilities.
Industries
Nr. of Employees
small (1-50)
Products
AAV gene therapy platform
A characterized AAV-based platform used to design and develop gene therapy candidates intended to minimize development risk.
Pipeline of preclinical and clinical gene therapy programs
A portfolio of gene therapy candidate programs targeting severe genetic diseases at preclinical and clinical stages.
AAV gene therapy platform
A characterized AAV-based platform used to design and develop gene therapy candidates intended to minimize development risk.
Pipeline of preclinical and clinical gene therapy programs
A portfolio of gene therapy candidate programs targeting severe genetic diseases at preclinical and clinical stages.
Services
End-to-end R&D support for AAV-based gene therapy programs, including vector design, preclinical development and translational activities.
Scalable manufacturing processes for AAV vectors intended to support clinical development and commercial supply.
Analytical assay development and laboratory testing to characterize gene therapy vectors and assess product quality.
Clinical strategy, medical oversight and program management for preclinical-to-clinical translation of gene therapies.
Program-level coordination and management of clinical supply chain activities for gene therapy studies.
Regulatory planning, interactions with authorities and implementation of quality systems to support submissions and product approvals.
End-to-end R&D support for AAV-based gene therapy programs, including vector design, preclinical development and translational activities.
Scalable manufacturing processes for AAV vectors intended to support clinical development and commercial supply.
Analytical assay development and laboratory testing to characterize gene therapy vectors and assess product quality.
Clinical strategy, medical oversight and program management for preclinical-to-clinical translation of gene therapies.
Program-level coordination and management of clinical supply chain activities for gene therapy studies.
Regulatory planning, interactions with authorities and implementation of quality systems to support submissions and product approvals.
Expertise Areas
- Gene therapy platform development
- Viral vector manufacturing and scale-up
- Analytical assay development for biologics
- Clinical development and medical affairs
Key Technologies
- AAV-based gene delivery
- Capsid engineering
- Novel gene delivery methods
- GMP bioprocessing for viral vectors